Medical OET · Test 02
Test 02 - Part C - Extract 2
Hello, I'm Dr Pamela Skelton, Consultant Cardiologist at this hospital, and I'm talking about the recent SPRINT study into the effects of setting lower…
Level: C2 · 71 sentences
Transcript
- Hello, I'm Dr Pamela Skelton, Consultant Cardiologist at this hospital,
- and I'm talking about the recent SPRINT study into the effects of setting lower blood-pressure targets,
- which in turn affects the advice and medication which patients are given.
- I'm going to describe the patients who were selected,
- how the trial was conducted
- and the implications of its results for us all as health professionals.
- First, the trial itself.
- It involved over 9000 hypertensive participants, aged 50-plus,
- most of whom were on blood-pressure medication.
- They were randomly assigned to one of two groups,
- one with a goal of less than 120 millimetres systolic BP,
- the other with a goal of less than 140 millimetres, the traditional standard.
- The intention was to follow these patients for 5 years,
- factoring in the usual drop-out rate.
- As it turned out, however, the trial was stopped after just 3 years
- thanks to an all cause mortality reduction of nearly 30% for the 120-group,
- which was definitive and shocking but wonderful.
- As I mentioned, the participants were over-fifties
- and it goes without saying that as people age, they develop more diseases and health problems as a matter of course.
- But there was a specific group of over-seventy-fives who did just as well as younger patients.
- Before the trial, some medics referred to the natural stiffening of the arteries with ageing,
- suggesting that a hundred-and-twenty was too low a target for the over-seventy-fives,
- risking an increase of dizzy spells which would affect general wellbeing.
- But this concern turned out to be unfounded.
- Others thought there'd be a failure to take the number of tablets needed to reach a BP of 120,
- especially among older participants.
- Again, this wasn't an issue.
- The average needed was just three per day.
- The over-seventy-fives, already on various drugs, didn't object to extra medication.
- Participants from this age group who didn't finish the trial were taken out because some conditions, which were already present, worsened;
- for example in some cases obesity levels rose too high.
- To manage their blood pressure, participants were given standard drugs,
- nothing experimental, just drugs that are readily available and low-cost.
- Another key factor was that blood pressure was measured in a very specific way.
- Rather than give patients an arm cuff for at-home 24-hour ambulatory monitoring,
- an automated machine was used at the hospital.
- This took three separate readings and averaged them.
- Also, readings were taken while staff were out of the room
- to avoid what's called 'white coat syndrome' in patients.
- Now, some of you may be familiar with the ACCORD study into blood pressure levels several years ago,
- which in some respects was similar to SPRINT.
- There are some differences, though.
- For example, ACCORD was about half the size of SPRINT,
- and unlike SPRINT, the ACCORD study allowed diabetic patients to take part.
- Despite this, in general, the ACCORD participants were rather lower risk than those in the SPRINT trial.
- Probably because of the slightly lower average age.
- The ACCORD trial didn't show a statistically significant benefit for overall cardiovascular outcomes,
- but there was a clear forty percent reduction in strokes,
- even though that was a secondary outcome.
- So, to summarise, the SPRINT trial seems to support 120 as a recommended blood pressure target.
- This is doubtless a landmark study
- and, importantly, one which was sponsored by government
- rather than by the interests of the pharmaceutical corporations.
- I recommend a note of caution though,
- as SPRINT does contradict previous findings.
- The Cochrane View in 2011, for example,
- said that lowering to under 140 didn't produce a change in the risk of death overall.
- However, we must bear in mind that Cochrane was looking retrospectively at trials which weren't actually focused on the same particular issue.
- So it's worth doing a full and systematic evaluation,
- to see where the SPRINT trial fits in with what we already know.
- It's interesting that a few GPs have already been working with older patients to hit lower blood-pressure goals,
- and the new data will doubtless encourage greater take-up of this more interventionist line of attack.
- But the SPRINT results don't mean that everyone with hypertension should be dropping to under a hundred and twenty.
- Plus, to achieve those lower levels,
- it's unlikely that lifestyle changes alone would be enough,
- it could well require several anti-hypertensive drugs as well.
- There remain some unanswered questions, of course.
- For example, whether other groups, like those with a lower heart-attack risk, need to keep their blood pressure that low.
- So, while SPRINT can help guide doctors' decisions about some patients,
- it doesn't mean that a new universal standard for blood pressure is in order.
- Instead, it's a good reason for everyone to discuss with their doctor, their own ideal and particular target.